+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Effects of long-term treatment in Wilson's disease with D-penicillamine and zinc sulphate

Effects of long-term treatment in Wilson's disease with D-penicillamine and zinc sulphate

Journal of Neurology 243(3): 269-273

The results of treatment with D-penicillamine (D-P) or zinc sulphate (Zn) in 67 newly diagnosed cases of Wilson's disease have been compared. All patients (7 with hepatic, 1 with psychiatric and 59 with neurological or preclinical forms) were fully compliant. During 12 years of observation, 34 patients received d-P and 33 Zn as the primary treatment. Fifteen patients (44%) discontinued D-P, in 10 cases owing to side effects. Four (12%) patients discontinued Zn, in 2 cases because of side-effects. One patient who received Zn deteriorated during the first few months after the initiation of therapy. The effectiveness of long-term treatment with D-P and Zn was similar in those patients who were able to continue the initial therapy. Zn was tolerated better than D-P; we suggest, therefore, that it may be recommended as an initial therapy for patients in the preclinical stage of Wilson's disease or with neurological presentation of the disease. More observation is needed for patients with the hepatic and psychiatric forms of the disease.

(PDF emailed within 1 workday: $29.90)

Accession: 008572924

Download citation: RISBibTeXText

PMID: 8936358

Related references

Long-term effects of a combination of D-penicillamine and zinc salts in the treatment of Wilson's disease in children. Experimental and Therapeutic Medicine 5(4): 1129-1132, 2013

Changes in zinc metabolism during long-term D-penicillamine treatment of patients with Wilson-Konovalov disease. Zhurnal Nevropatologii i Psikhiatrii Imeni S.S. Korsakova 84(3): 356-359, 1984

Oral zinc sulphate as long-term treatment in Wilson's disease (hepatolenticular degeneration). European Neurology 18(3): 205-211, 1979

Zinc sulphate therapy for Wilson's disease after acute deterioration during treatment with low-dose D-penicillamine. Journal of Internal Medicine 229(6): 549-552, 1991

Withdrawal of penicillamine from zinc sulphate-penicillamine maintenance therapy in Wilson's disease: promising, safe and cheap. Journal of the Neurological Sciences 264(1-2): 129-132, 2007

Treatment with D-penicillamine or zinc sulphate affects copper metabolism and improves but not normalizes antioxidant capacity parameters in Wilson disease. Biometals 27(1): 207-215, 2015

Zinc sulphate by mouth: an effective alternative to penicillamine in Wilson's disease. Le zinc en medecine et biologie: 179-181, 1987

Wilson's disease (experience of long-term treatment with penicillamine---con penicilamina. Revista Clinica Espanola 133(5): 451-454, 1974

Long-term treatment of Wilson's disease with D-penicillamine. Report on 20 cases. Deutsche Medizinische Wochenschrift 92(37): 1657-1662, 1967

Liver copper determination in long-term treatment of Wilson's disease with D-penicillamine. Die Medizinische Welt 32(3): 109-110, 1981

The effect of long-term treatment with d-penicillamine on the humoral immune response in patients with Wilson's disease. Materia Medica Polona. Polish Journal of Medicine and Pharmacy 8(1): 48-50, 1976

The effect of long term treatment with penicillamine on the copper content in the liver in patients with Wilson's disease. Acta Hepato-Gastroenterologica 22(5): 292-296, 1975

Effects of long-term zinc treatment in Japanese patients with Wilson disease: efficacy, stability, and copper metabolism. Translational Research 156(6): 350-357, 2010

Long-term D-penicillamine therapy of Wilson's disease in childhood. Changes in blood coagulation and effects on the haematopoetic system. Wiener Klinische Wochenschrift 85(8): 122-125, 1973

Detection of D-penicillamine in skin lesions in a case of dermal elastosis after a previous long-term treatment for Wilson's disease. Journal of the European Academy of Dermatology and Venereology 29(2): 383-386, 2015